Research Peptide Legal Status: US, UK, EU, CA, AU
This page is general information, current as of October 14, 2026. It is not legal advice. Peptide regulation is changing quickly, and the rules for any one product depend on the compound, the claims made and where you are. Check the primary sources linked here and speak to a qualified lawyer before relying on any of it.
Summary
| Market | Main regulator | Unapproved peptides sold for people | Personal import | Recent enforcement |
|---|---|---|---|---|
| United States | FDA | Unapproved new drugs; “research use only” labels not accepted [7] | Illegal in most circumstances [6] | Warning letters 2023–2026 [24] [7]; a prison sentence in 2026 [8] |
| United Kingdom | MHRA | Medicines rules apply when medicinal claims are made [11]; retatrutide not authorized [10] | Not covered here; seek advice | Raids and arrests, 2025–2026 [12] |
| European Union | EMA and national regulators | Medicines need a marketing authorization [13] | Varies by country | Austria warns buyers can face consequences [15] |
| Canada | Health Canada | Injectable peptides regulated as prescription drugs [16] | Residents generally can’t import prescription drugs [17] | Seizures and public advisories, 2025–2026 [18] [16] |
| Australia | TGA | Unlawful to import, advertise, manufacture or supply unapproved peptides [19] | Prescription-only medicines need an Australian prescription [21] | Seizures and search warrants, 2026 [19] |
United States
Unapproved new drugs. The FDA treats peptides sold for human use without approval as unapproved new drugs [7] [24]. Its warning letters reject “research use only” labels when a seller’s website shows the products are meant for people [7] [24]. A March 2026 letter, for example, concluded that a seller’s retatrutide and tirzepatide products were unapproved new drugs despite “Research Use Only” labels [7]. A 2023 letter treated BPC-157 injections and nasal sprays sold online the same way [24]. See our explainer on RUO labels.
Compounding is a separate, narrow route. Licensed pharmacies can sometimes compound drugs from bulk substances [1]. Under an interim policy, the FDA sorts nominated substances into three categories, two of which matter here [1]:
- Category 1: substances for which the FDA does not intend to act against compounders that meet its conditions [1].
- Category 2: substances with identified significant safety risks [1].
As of its April 22, 2026 update, the FDA’s safety-risk page lists BPC-157, TB-500, CJC-1295, KPV, MOTS-c, epitalon, selank, semax, thymosin alpha-1, injectable GHK-Cu and several others under “bulk drug substances nominated but withdrawn”. These were previously in category 2. GHRP-2, GHRP-6 and ipamorelin remain in category 2 under the 503B policy for outsourcing facilities, and kisspeptin-10 remains in category 2 under the 503A policy [2].
The July 2026 advisory votes. On July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee voted 8–6, with one abstention, in favor of BPC-157 for compounding [3]. Trade press reported the same tally for KPV and TB-500, and 7–5 with two abstentions for MOTS-c [4]. FDA staff scientists opposed adding the peptides [4]. The votes are non-binding, and formal notice-and-comment rulemaking is needed before pharmacies have clear authority to compound them [4]. Even then, compounding means a prescription filled by a licensed pharmacy, not a research-chemical website.
GLP-1s. Retatrutide and cagrilintide cannot be used in compounding under federal law [5]. The FDA has warned companies selling semaglutide, tirzepatide, retatrutide and related compounds as “research” products directly to consumers [5]. See our guide to gray-market GLP-1 risks.
Personal importation. The FDA says that in most circumstances it is illegal for individuals to import drugs for personal use [6]. It describes limited enforcement discretion, for example for a serious condition where treatment isn’t available domestically and the product isn’t promoted to US consumers [6].
Criminal cases. The owner of Paradigm Peptides was sentenced to 5 years and 10 months in July 2026 after pleading guilty [8]. More cases are on our alerts page.
United Kingdom
Medicines law. Medicines in the UK are regulated under the Human Medicines Regulations 2012 [9]. The MHRA has said that when clinics make medicinal claims for peptide treatments, the products are treated as medicines under those regulations, and that it will act against breaches [11].
GLP-1s and retatrutide. The MHRA says retatrutide has not been authorized for use in the UK, so “anyone selling this product is doing so illegally” [10]. The MHRA says authorized GLP-1 medicines such as Wegovy and Mounjaro should only be taken as prescribed by a healthcare professional [10]. Its advice is to check that a pharmacy is registered with the General Pharmaceutical Council, and to walk away from any offer of a GLP-1 without a prescription [10].
Enforcement. The MHRA’s Criminal Enforcement Unit has carried out several raids targeting the illegal supply of weight-loss medicines [12]. In May 2026, it raided a site near Northampton believed to make unlicensed weight-loss medicines, including retatrutide and tirzepatide, as well as peptide products. Officers recovered about 12,000 doses of unlicensed weight-loss medicines and arrested two people on suspicion of offenses under the Human Medicines Regulations 2012 [12].
European Union
Marketing authorization. EU law requires a marketing authorization before a medicinal product is placed on the market in a member state [13]. Enforcement is mostly carried out by national regulators, such as Austria’s [15].
Buying online. The EMA has warned about falsified medicines in the supply chain. In October 2023 it reported falsified Ozempic pens found at wholesalers in the EU and the UK, and it said people buying medicines online should only use legal pharmacies [14].
A national example. In May 2026, Austria’s medicines regulator said that peptide products it classifies as medicinal products lack the required marketing authorization, and that placing them on the market or importing them is prohibited [15]. It said “research chemical” designations are irrelevant under pharmaceutical law, and that purchasers may face legal consequences [15].
Canada
Prescription drugs. Health Canada says peptides are generally regulated as prescription drugs [16]. Unauthorized drug products are illegal and haven’t been assessed for safety, efficacy and quality [16]. “Research use only” labeling does not make them legal or exempt from requirements [16]. Authorized drugs carry an eight-digit Drug Identification Number (DIN) [16]. Health Canada is working with the Canada Border Services Agency to stop unauthorized shipments [16].
Personal importation. Residents of Canada are generally not allowed to bring prescription drugs into Canada, whether carried across the border or delivered by mail or courier [17].
Enforcement. Health Canada has seized products and issued public advisories naming sellers [16] [18]. One example is an August 2025 advisory about injectable peptides seized from, and sold by, Canada Peptide [18].
Australia
Unlawful supply. The TGA says it is unlawful to import, advertise, manufacture and supply unapproved peptide products in Australia [19]. Penalties include civil penalties of up to A$1.82 million per breach for individuals and A$18.2 million per breach for corporations, and criminal penalties of up to 7 years’ imprisonment [19]. In June 2026, the TGA added unapproved peptide products to its compliance priorities [20].
Promoters too. The TGA has warned that influencers, affiliates, online sellers and anyone else promoting unapproved peptide products may be held accountable for unlawful advertising [19] [23].
Scheduling. Sport Integrity Australia lists BPC-157 in Schedule 4 (prescription-only medicines) and in clause 5 of Appendix D of the Poisons Standard [22]. Clause 5 covers poisons that must not be possessed without authority, for example other than under a legal prescription [22].
Personal importation. Under the Personal Importation Scheme, prescription-only medicines need a valid Australian prescription or written authority at the time of import [21]. Quantities are capped, and the scheme doesn’t cover controlled substances or goods prohibited under customs rules [21].
What this means for how we publish
We publish facts about vendors, prices and tests so buyers can see what is on the market. We don’t publish dosing or usage guidance. A vendor appearing on our vendor index or in our market pages doesn’t mean buying from it is legal where you live. Regulatory events are logged on our alerts page as they happen.
Frequently asked questions
Is BPC-157 legal in the US?
The FDA has treated BPC-157 products sold online for human use as unapproved new drugs. In July 2026 an FDA advisory committee voted 8-6 in favour of allowing it in pharmacy compounding, but that vote is non-binding and needs formal rulemaking. Not legal advice.
Can I import research peptides for personal use?
Generally no. The FDA says it is illegal in most circumstances to import unapproved drugs for personal use. Health Canada says residents generally can't import prescription drugs, including by mail. Australia requires a valid Australian prescription for prescription-only medicines. Not legal advice.
Does a 'research use only' label change any of this?
No. Regulators in the US, Canada and Austria have said such labels don't make products legal when the circumstances show they are meant for people. Australia's TGA says it is unlawful to import, advertise, manufacture or supply unapproved peptide products.